Sorry, you need to enable JavaScript to visit this website.

How Was the Duration of Treatment Determined | XARELTO® (rivaroxaban) HCP

How was the duration of treatment (3, 6, or 12 months) determined in the EINSTEIN–DVT and EINSTEIN–PE studies?

In EINSTEIN-DVT and EINSTEIN-PE, the enrolling physician determined treatment duration at the time of randomization based on the patient’s profile and local treatment preferences.1,2

For the DVT study, approximately 63% of all patients were allocated to 6 months of treatment, while 25% were allocated to 12 months of treatment.3 In the PE study, approximately 57% and 37% of all patients were allocated to 6 months and 12 months of treatment, respectively.4

For VTE prophylaxis in acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.

DVT = deep vein thrombosis; PE = pulmonary embolism.